A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Article

authors

  • Robbins, PF
  • Kassim, SH
  • Tran, TL
  • Crystal, JS
  • Morgan, RA
  • Feldman, SA
  • Yang, JC
  • Dudley, ME
  • Wunderlich, JR
  • Sherry, RM
  • Kammula, US
  • Hughes, Marybeth S.
  • Restifo, NP
  • Raffeld, M
  • Lee, CC
  • Li, YF
  • El-Gamil, M
  • Rosenberg, SA

publication date

  • 2015

published in

PubMed Central ID

  • pmc4361810

start page

  • 1019

end page

  • 27

volume

  • 21

issue

  • 5